Effect of Herbal Medicine on Bone Turnover Markers in Pre- and Peri/postmenopausal Women: An Overview of Meta-Analyses
Authors:
- Masoudeh BabakhanianMBMasoudeh Babakhanian
- Fahimeh ShakeriFSFahimeh Shakeri
- Farzaneh Rashidi FakariFFFarzaneh Rashidi Fakari
- Sara SaadatSSSara Saadat
- Morvarid IraniMIMorvarid Irani
- Adeleh KhodabakhshiAKAdeleh Khodabakhshi
- Masumeh GhazanfarpourMGMasumeh Ghazanfarpour
- Roghaie KhoshkholghRKRoghaie Khoshkholgh
Open Access
- 27 August 2023
- journal article
- research article
- Published by Brieflands in Middle East Journal of Rehabilitation and Health Studies
- Vol. 11 (3)
Abstract
Background: Osteoporosis is a chronic debilitating disease that poses a serious challenge to humanity. Osteoporosis and its related complications impose huge direct costs on the health system. Objectives: The purpose of this study was to critically evaluate the effects of soy isoflavones and phytoestrogens on bone turnover markers in pre- and peri/postmenopausal women. Methods: Three main databases [MEDLINE, Scopus, and Cochrane Central Register of Controlled Trials (CENTRAL)] were searched to explore published meta-analyses. The methodological quality was assessed by AMSTAR. Results: Four meta-analyses were included in this overview. Isoflavones and phytoestrogens significantly decreased urinary pyridinoline (Pyd). The subgroup analysis of Pyd indicated that isoflavones were more effective in overweight/obese individuals, and a dosage of < 90 mg/day Deoxypyridinoline (Dpyd) had a desirable effect on phytoestrogens. However, the findings regarding the effect of isoflavones on Dpyd were controversial. The subgroup analysis of Pyd showed that isoflavones in the form of extract and tablet caused a significant decrease; nevertheless, soy foods with isoflavones and isolated soy protein failed to induce a significant drop. Isoflavones decreased Dpyd even during the intervention but were unable to induce a significant decrease. Moreover, although isoflavones considerably reduced Dpyd in postmenopausal women, it was non-significant in peri-menopausal women. The bone formation markers of bone-specific alkaline phosphatase, N-telopeptide, and osteocalcin were not significantly different between soy isoflavones and the control group. Osteoprotegerin was significantly higher, and C-telopeptide was significantly lower in women receiving isoflavones than in women in the control group. Conclusions: The current overview showed that isoflavones might decrease some urinary bone resorption markers. However, it had no significant effect on bone formation markers and influenced turnover markers in menopausal women.Keywords
This publication has 24 references indexed in Scilit:
- Effect of exercise training combined with isoflavone supplementation on bone and lipids in postmenopausal women: A randomized clinical trialJournal of Bone and Mineral Research, 2012
- Effects of ground and joint reaction force exercise on lumbar spine and femoral neck bone mineral density in postmenopausal women: a meta-analysis of randomized controlled trialsBMC Musculoskeletal Disorders, 2012
- Isoflavones versus hormone therapy for reduction of vertebral fracture riskMenopause, 2010
- Prevention of bone resorption by intake of phytoestrogens in postmenopausal women: a meta-analysisAGE, 2010
- Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosisJoint Bone Spine, 2010
- Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trialsEuropean Journal of Clinical Nutrition, 2007
- The effects of short-term hormone replacement therapy on long-term bone mineral densityClimacteric, 2007
- The Balance Between Concurrent Activation of ERs and PPARs Determines Daidzein-Induced Osteogenesis and AdipogenesisJournal of Bone and Mineral Research, 2004
- Soybean isoflavones inhibit tumor necrosis factor-α-induced apoptosis and the production of interleukin-6 and prostaglandin E2 in osteoblastic cellsPhytochemistry, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002